Moderna's Growth Strategy Seen as Reassuring Investors -- Market Talk

Dow Jones01-24 04:05

1505 ET - Investors are acclimating to Moderna's growth strategy following a drop-off in Covid-19 vaccine sales, possibly explaining the stock more than doubling since early December, Bank of America analyst Alec Stranahan writes in a note. The growth is likely a result of the company's improving cost structure and stabilizing topline, as well as recent five-year data on intismeran that showed solid durability ahead of expected Phase 2 and 3 readouts in the coming months. The company has also indicated that its U.S. litigation could stretch to 2028 or beyond with appeals. "While none of these are significant share movers individually, we think investors may be getting more comfortable with the turnaround story and buying in ahead of the intismeran data," he writes. Still, he sees the stock climb as overshooting near-term pipeline value. Shares slide 8.7%. (elias.schisgall@wsj.com)

(END) Dow Jones Newswires

January 23, 2026 15:05 ET (20:05 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment